ALLOGENE THERAPEUTICS ($ALLO) posted quarterly earnings results for Q4 2025 on Thursday, March 12th. The company reported earnings of -$0.17 per share, beating estimates of -$0.22 by $0.05. The company also reported revenue of $0, equaling estimates of $0 by $0.
Stock price change since market close: +4.18%
You can see Quiver Quantitative's $ALLO stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
ALLOGENE THERAPEUTICS Insider Trading Activity
ALLOGENE THERAPEUTICS insiders have traded $ALLO stock on the open market 10 times in the past 6 months. Of those trades, 0 have been purchases and 10 have been sales.
Here’s a breakdown of recent trading of $ALLO stock by insiders over the last 6 months:
- DAVID D CHANG (President and CEO) sold 95,269 shares for an estimated $171,484
- ZACHARY ROBERTS (EVP of R&D) has made 0 purchases and 2 sales selling 61,969 shares for an estimated $104,168.
- GEOFFREY M. PARKER (CHIEF FINANCIAL OFFICER) has made 0 purchases and 2 sales selling 60,745 shares for an estimated $88,410.
- EARL MARTIN DOUGLAS (SVP, General Counsel) sold 22,900 shares for an estimated $40,304
- BENJAMIN MACHINAS BENESKI (SVP, Chief Technical Officer) has made 0 purchases and 3 sales selling 15,467 shares for an estimated $32,561.
- ANNIE YOSHIYAMA (SVP, Finance) sold 4,167 shares for an estimated $7,167
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
ALLOGENE THERAPEUTICS Hedge Fund Activity
We have seen 80 institutional investors add shares of ALLOGENE THERAPEUTICS stock to their portfolio, and 86 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CAPITAL WORLD INVESTORS removed 11,150,000 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $13,826,000
- DARWIN GLOBAL MANAGEMENT, LTD. removed 10,479,791 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $12,994,940
- FORESITE CAPITAL MANAGEMENT VI LLC removed 2,875,357 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $3,565,442
- CANDRIAM S.C.A. added 2,305,644 shares (+inf%) to their portfolio in Q4 2025, for an estimated $3,158,732
- UBS GROUP AG removed 2,181,564 shares (-61.1%) from their portfolio in Q4 2025, for an estimated $2,988,742
- PATIENT SQUARE CAPITAL LP added 1,982,360 shares (+66.5%) to their portfolio in Q4 2025, for an estimated $2,715,833
- CITADEL ADVISORS LLC removed 1,860,137 shares (-13.3%) from their portfolio in Q4 2025, for an estimated $2,548,387
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
ALLOGENE THERAPEUTICS Analyst Ratings
Wall Street analysts have issued reports on $ALLO in the last several months. We have seen 0 firms issue buy ratings on the stock, and 1 firms issue sell ratings.
Here are some recent analyst ratings:
- JP Morgan issued a "Underweight" rating on 10/10/2025
To track analyst ratings and price targets for ALLOGENE THERAPEUTICS, check out Quiver Quantitative's $ALLO forecast page.
ALLOGENE THERAPEUTICS Price Targets
Multiple analysts have issued price targets for $ALLO recently. We have seen 2 analysts offer price targets for $ALLO in the last 6 months, with a median target of $6.5.
Here are some recent targets:
- Reni Benjamin from Citizens set a target price of $5.0 on 01/09/2026
- Michael Yee from UBS set a target price of $8.0 on 01/07/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
